BioSpace News Archive

The number of illicit fentanyl seizures by law enforcement in the United States grew by more than 1,700 percent between 2017 and 2023, according to a new analysis.

Owens & Minor, Inc. announced that Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer and Jonathan Leon, the Company’s Senior Vice President-Finance and Corporate Treasurer, will be participating in a webcasted fireside chat at 5:20 p.m. Eastern Daylight Time on Wednesday, May 15, 2024 at BofA Securities’ 2024 Health Care Conference in Las Vegas, Nevada.

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial.

Pharvaris announced the acceptance of abstracts for presentation at three upcoming congresses: the 20th Annual Congress of International Drug Discovery Science and Technology ; the 2024 Eastern Allergy Conference ; and the European Academy of Allergy and Clinical Immunology Congress 2024.

MC2 Therapeutics confirms it has received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration with respect to its first-in-class, oral drug candidate MC2-32 for the treatment of Hidradenitis Suppurativa.

BioCryst Pharmaceuticals, Inc. announced that the Federal Commission for Protection against Health Risks in Mexico has granted approval for oral, once-daily ORLADEYO® for the prophylaxis of hereditary angioedema attacks in adults and pediatric patients 12 years of age or older.

Apogee Therapeutics, Inc., a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology indications, reported pipeline highlights and first quarter financial results.

Tourmaline Bio, Inc. announced its financial results for the first quarter ended March 31, 2024 and outlined recent business highlights.

Galera Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and provided recent corporate updates.

TScan Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.